Clinical Trials for Psoriasis

137 psoriasis trials indexed, 41 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Psoriasis

Psoriasis is a chronic skin condition that causes cells to build up rapidly on the surface of the skin. This buildup forms scales and red patches that can be itchy and sometimes painful. The underlying cause involves an immune system problem where the body mistakenly attacks its own skin cells. This immune response speeds up the growth cycle of skin cells, leading to thickened, inflamed areas. Doctors diagnose psoriasis mainly by examining the skin and considering medical history. In some cases, a skin biopsy may be performed to rule out other conditions.

Common symptoms include red patches covered with silvery scales, dry or cracked skin that may bleed, and itching or burning sensations. Psoriasis often appears between the ages of 15 and 35 but can develop at any age. It affects men and women equally and occurs worldwide. Certain groups are more at risk, such as people with a family history of psoriasis, those with autoimmune diseases, and individuals exposed to triggers like stress, infections, or certain medications. Environmental factors and lifestyle choices, including smoking and obesity, can also increase the risk.

Psoriasis is more than a skin problem; it has significant medical and social impacts. About 2-3% of the global population lives with psoriasis, making it a common chronic condition. It can lead to complications like psoriatic arthritis, which affects joints and causes pain and stiffness. Socially, psoriasis can affect self-esteem and mental health due to visible skin changes and stigma. The economic burden is also notable, with costs related to treatment and lost work productivity. Understanding psoriasis helps patients and caregivers manage the condition better and seek appropriate care.

The Psoriasis Treatment Landscape

First-line treatment for psoriasis usually begins with topical therapies. These include corticosteroids, vitamin D analogues, and moisturizers that help reduce inflammation and slow skin cell growth. For mild to moderate cases, these treatments are often effective and preferred due to their lower risk of side effects. Phototherapy, which uses ultraviolet light, is another early option for patients who do not respond well to topical treatments. Doctors typically recommend starting with these less invasive methods before moving to stronger medications.

When psoriasis is moderate to severe or does not improve with first-line treatments, second- and third-line options come into play. These include systemic drugs that work throughout the body. Common drug classes are biologics, which target specific parts of the immune system, and traditional systemic medications like methotrexate and cyclosporine. Biologics such as adalimumab and etanercept have become widely used for their ability to control symptoms more effectively. Other options include newer oral medications that inhibit immune pathways involved in psoriasis.

Despite many available treatments, some patients still face challenges. Certain subgroups, such as those with psoriatic arthritis or extensive skin involvement, may respond poorly to standard therapies. Resistance to drugs can develop, and side effects like increased infection risk or liver toxicity limit long-term use. Research focuses on closing these gaps by finding treatments that are safer, more effective, and tailored to individual patient needs. Clinical trials play a key role in testing new approaches to address these unmet needs in psoriasis care.

Why Clinical Trials Matter for Psoriasis

Clinical trials offer patients with psoriasis the chance to access new treatments before they become widely available. These studies provide close monitoring by healthcare professionals, which can improve overall care during the trial. According to ClinicalTrials.gov, there are currently 137 psoriasis clinical trials indexed, with 41 actively recruiting participants. Taking part in a trial also contributes to scientific knowledge that can help future patients. For those living with psoriasis, joining a clinical trial may open doors to options not found in standard care.

However, clinical trials come with risks and challenges. The effectiveness of the new treatment is not guaranteed, and some participants may receive a placebo instead of the active drug. Additional clinic visits and tests are often required, which can be time-consuming. Side effects may occur, and long-term safety is sometimes unknown. Patients should carefully weigh these factors and discuss them with their healthcare providers before enrolling in a study.

The sponsors of psoriasis clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in developing and testing new therapies. ClinicalTrials.gov serves as a central registry where patients and caregivers can find information about ongoing and upcoming studies. This transparency helps individuals make informed decisions about participation and stay updated on research progress in psoriasis treatment.

What to Look for in a Psoriasis Clinical Trial

Clinical trials for psoriasis are divided into four phases. Phase 1 trials focus on safety and dosage, often involving a small number of healthy volunteers or patients. Phase 2 trials test the effectiveness of a treatment and gather more safety data. Phase 3 trials involve larger groups to confirm effectiveness, monitor side effects, and compare with standard treatments. Phase 4 trials occur after a treatment is approved to track long-term effects and gather additional information. For psoriasis, most trials are in Phase 3, with 41 studies, followed by 20 in Phase 4, 18 in Phase 2, and 18 with no assigned phase.

Inclusion criteria for psoriasis clinical trials usually specify age ranges, often adults 18 years and older. Some trials may include adolescents depending on the treatment being studied. Participants often need to have a confirmed diagnosis of psoriasis with a certain severity level, such as moderate to severe plaque psoriasis. Prior treatments might be considered, with some trials requiring participants to have tried and not responded well to standard therapies. Biomarkers or specific disease markers may be required in some studies to better understand how the treatment works. Disease duration is also important, with some trials focusing on newly diagnosed patients and others on those with long-term psoriasis.

Exclusion criteria help protect participants and ensure clear results. Common reasons for exclusion include having other significant health problems, such as heart disease or infections, which could increase risks or interfere with the treatment. Drug interactions are also a concern, so participants may need to avoid certain medications during the trial. Safety thresholds like liver or kidney function tests are used to exclude patients who might face higher risks from the treatment. These criteria help researchers focus on patients who can safely participate and provide reliable data.

From a patient’s perspective, practical factors matter a lot. Trial duration can vary from a few weeks to several months or longer. Visit schedules may require frequent trips to the research site, which can be challenging depending on location and personal commitments. Travel needs and costs should be considered as some trials may offer support. When speaking with the research team, patients should ask: What are the possible side effects? How often will visits be required? Will I need to stop my current psoriasis treatments? What happens if I decide to leave the trial early? These questions help patients understand what to expect and decide if a trial fits their needs.

Primary Sources and Further Reading

For those interested in learning more about psoriasis and clinical trials, it is important to use reliable and trustworthy sources. These websites offer detailed information about psoriasis, treatment options, and how clinical trials work. They can help patients and caregivers make informed decisions and find ongoing studies that might be suitable.

Latest Research and Emerging Treatments for Psoriasis (2026)

Recent psoriasis research is exploring new drugs that may improve treatment options for patients. One study is testing guselkumab, a biologic that targets a specific protein involved in inflammation, in children aged 6 to under 18 with chronic plaque psoriasis (NCT03451851). This drug works by blocking interleukin-23, a key driver of the immune response that causes skin symptoms. The trial compares guselkumab to placebo and etanercept, aiming to see if it can clear skin better and improve quality of life for young patients.

Another important psoriasis new treatment in 2026 is tildrakizumab, which is being studied in adults with active psoriatic arthritis who have not used anti-TNF drugs before (NCT04314531). Like guselkumab, tildrakizumab blocks interleukin-23, which may reduce joint inflammation and skin symptoms. This trial is testing whether tildrakizumab improves symptoms and daily functioning compared to placebo. For patients, this could mean more targeted options that address both skin and joint problems.

Long-term safety studies are also underway for deucravacitinib, a drug that works differently by inhibiting an enzyme called TYK2 involved in the immune system’s signaling (NCT07116967). This trial compares deucravacitinib to ustekinumab, another biologic that blocks interleukin-12 and interleukin-23. Understanding safety over time, especially regarding heart health, is important for people with moderate-to-severe plaque psoriasis who may need ongoing treatment. These new drugs for psoriasis could offer more choices with different ways to control symptoms and improve patient experience.

Frequently asked questions about Psoriasis trials

How do I find Psoriasis clinical trials?

The authoritative source for Psoriasis clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 137 psoriasis studies are currently indexed. You can search by entering "psoriasis" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new psoriasis trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Psoriasis trials in?

Across the 137 psoriasis trials TrialsAlert indexes, the most common phase is Phase 3. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Psoriasis clinical trials are currently recruiting?

As of the latest scan, 41 psoriasis trials have a "Recruiting" status on ClinicalTrials.gov, out of 137 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting psoriasis trial matches their tracked condition.

Stay informed about psoriasis research

Get a weekly briefing with the trials that matter most.

Start monitoring psoriasis trials